D S Baldwin

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. ncbi request reprint Evidence-based pharmacotherapy of Generalized Anxiety Disorder
    David S Baldwin
    Clinical Neurosciences Division, Faculty of Medicine, Health and Life Sciences, University of Southampton, UK
    Int J Neuropsychopharmacol 8:293-302. 2005
  2. ncbi request reprint Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study
    David S Baldwin
    Neuroscience Division, School of Medicine, University of Southampton, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK
    Br J Psychiatry 189:264-72. 2006
  3. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
  4. doi request reprint An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder
    David S Baldwin
    University of Southampton Faculty of Medicine, Southampton, UK
    World J Biol Psychiatry 13:510-6. 2012
  5. doi request reprint Antidepressant drugs and sexual dysfunction
    David S Baldwin
    DM, FRCPsych, University Department of Psychiatry, College Keep, 4 12 Terminus Terrace, Southampton SO14 3DT, UK
    Br J Psychiatry 202:396-7. 2013
  6. doi request reprint Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
    David S Baldwin
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom
    Curr Med Res Opin 28:1717-24. 2012
  7. doi request reprint Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
    David S Baldwin
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
    Int Clin Psychopharmacol 27:197-207. 2012
  8. doi request reprint A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
    David S Baldwin
    Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, United Kingdom
    Eur Neuropsychopharmacol 22:482-91. 2012
  9. doi request reprint Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    David S Baldwin
    University of Southampton, UK
    Eur Neuropsychopharmacol 22:137-42. 2012
  10. ncbi request reprint Pharmacological treatment of generalized anxiety disorder
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Curr Top Behav Neurosci 2:453-67. 2010

Collaborators

Detail Information

Publications60

  1. ncbi request reprint Evidence-based pharmacotherapy of Generalized Anxiety Disorder
    David S Baldwin
    Clinical Neurosciences Division, Faculty of Medicine, Health and Life Sciences, University of Southampton, UK
    Int J Neuropsychopharmacol 8:293-302. 2005
    ..The management of patients who do not respond to first-line treatment is uncertain, but some patients may benefit from certain tricyclic antidepressants, buspirone, or pregabalin...
  2. ncbi request reprint Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study
    David S Baldwin
    Neuroscience Division, School of Medicine, University of Southampton, Royal South Hants Hospital, Graham Road, Southampton SO14 0YG, UK
    Br J Psychiatry 189:264-72. 2006
    ..It is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder...
  3. ncbi request reprint Discontinuation symptoms in depression and anxiety disorders
    David S Baldwin
    Clinical Neurosciences Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 10:73-84. 2007
    ..Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment...
  4. doi request reprint An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder
    David S Baldwin
    University of Southampton Faculty of Medicine, Southampton, UK
    World J Biol Psychiatry 13:510-6. 2012
    ..To gain insight into the experience and practice of psychiatrists in the pharmacological management of patients with generalized anxiety disorder (GAD)...
  5. doi request reprint Antidepressant drugs and sexual dysfunction
    David S Baldwin
    DM, FRCPsych, University Department of Psychiatry, College Keep, 4 12 Terminus Terrace, Southampton SO14 3DT, UK
    Br J Psychiatry 202:396-7. 2013
    ..Sexual dysfunction during antidepressant treatment is typically associated with many possible causes, but the risk of dysfunction varies with differing antidepressants, and should be considered when selecting an antidepressant...
  6. doi request reprint Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
    David S Baldwin
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom
    Curr Med Res Opin 28:1717-24. 2012
    ..The primary objective of this study was to evaluate the safety and tolerability of the investigational drug vortioxetine (Lu AA21004) in the long-term treatment of patients with major depressive disorder...
  7. doi request reprint Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
    David S Baldwin
    Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
    Int Clin Psychopharmacol 27:197-207. 2012
    ..In this study, Lu AA21004 5 or 10 mg/day was efficacious in preventing relapse and was well tolerated in the maintenance treatment of GAD...
  8. doi request reprint A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
    David S Baldwin
    Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, United Kingdom
    Eur Neuropsychopharmacol 22:482-91. 2012
    ..Findings on secondary outcome measures, using MMRM instead of LOCF, were supportive of likely efficacy for Lu AA21004 5mg and 10mg and duloxetine. Lu AA21004 (2.5, 5 and 10 mg) was well tolerated...
  9. doi request reprint Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    David S Baldwin
    University of Southampton, UK
    Eur Neuropsychopharmacol 22:137-42. 2012
    ....
  10. ncbi request reprint Pharmacological treatment of generalized anxiety disorder
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Curr Top Behav Neurosci 2:453-67. 2010
    ....
  11. ncbi request reprint A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
    Int Clin Psychopharmacol 21:159-69. 2006
    ..During taper and cessation of treatment, patients in the paroxetine group demonstrated significantly more discontinuation symptoms relative to escitalopram based on the Discontinuation Emergent Signs and Symptoms scores...
  12. ncbi request reprint Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
    David S Baldwin
    Division of Clinical Neurosciences, University of Southampton, Southampton, UK
    J Psychopharmacol 19:567-96. 2005
    ..The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments...
  13. ncbi request reprint Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670
    David Baldwin
    Clinical Neuroscience Division, University of Southampton, Southampton, UK
    J Psychopharmacol 22:55-63. 2008
    ..3%). Double-blind treatment with VML-670 offered no significant advantage over placebo on the primary outcome measure in the overall sample. Further studies may be warranted in larger groups of male patients with sexual dysfunction...
  14. ncbi request reprint Escitalopram therapy for major depression and anxiety disorders
    David S Baldwin
    Clinical Neuroscience Division, University Department of Mental Health, Royal South Hants Hospital, Southampton, England
    Ann Pharmacother 41:1583-92. 2007
    ..Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability...
  15. ncbi request reprint Room for improvement in the pharmacological treatment of anxiety disorders
    D S Baldwin
    Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK
    Curr Pharm Des 14:3482-91. 2008
    ....
  16. ncbi request reprint The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going?
    David S Baldwin
    Department of Psychiatry, Royal South Hants Hospital, Southampton, UK
    CNS Spectr 14:5-12. 2009
    ..Future guidelines will be influenced by emerging data with both established and novel drug treatments, and through better identification of patient groups that are likely to respond preferentially to particular interventions...
  17. doi request reprint How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK
    Hum Psychopharmacol 24:269-75. 2009
    ....
  18. doi request reprint Manifesto for a European anxiety disorders research network
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton School of Medicine, Southampton, UK
    Eur Neuropsychopharmacol 20:426-32. 2010
    ..The Anxiety Disorders Research Network (ADRN) has been adopted within the ECNP-NI: this consensus statement summarises its overall aims and objectives...
  19. doi request reprint Evidence-based pharmacological treatment of generalized anxiety disorder
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, UK
    Int J Neuropsychopharmacol 14:697-710. 2011
    ..There have been few investigations of the further management of patients who have not responded to first-line treatment, but switching to another evidence-based treatment, or augmentation approaches may be beneficial...
  20. ncbi request reprint Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine
    David Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southhampton, UK
    J Psychopharmacol 20:91-6. 2006
    ..Sexual function and satisfaction in depressed patients improves during double-blind acute treatment with reboxetine or paroxetine, but this improvement is greater and more rapid with reboxetine...
  21. ncbi request reprint Escitalopram in the treatment of generalized anxiety disorder
    David S Baldwin
    Division of Clinical Neurosciences, University Department of Mental Health, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
    Expert Rev Neurother 5:443-9. 2005
    ..In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine...
  22. ncbi request reprint Sexual dysfunction associated with antidepressant drugs
    David S Baldwin
    University Department of Mental Health, RSH Hospital, RSH Hospital, Graham Road, Southampton, SO14 0YG, UK
    Expert Opin Drug Saf 3:457-70. 2004
    ....
  23. ncbi request reprint A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment
    D S Baldwin
    Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK
    J Psychopharmacol 15:161-5. 2001
    ..Headache and somnolence were the most common reported adverse events in both treatment groups. Both nefazodone and paroxetine maintain their efficacy in continuation treatment, and both are generally well tolerated...
  24. ncbi request reprint Clinical experience with paroxetine in social anxiety disorder
    D S Baldwin
    Department of Mental Health, University of Southampton, UK
    Int Clin Psychopharmacol 15:S19-24. 2000
    ..Taken together, these studies confirm that paroxetine is an effective and well tolerated treatment for patients with social anxiety disorder...
  25. ncbi request reprint Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence
    David Baldwin
    Clinical Neuroscience Division, University of Southampton, Southampton, UK
    J Psychopharmacol 19:134-5. 2005
  26. ncbi request reprint Placebo-controlled studies in depression: necessary, ethical and feasible
    David Baldwin
    University Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton, UK
    Eur Arch Psychiatry Clin Neurosci 253:22-8. 2003
    ..Placebo-controlled studies of new antidepressants are justified, both scientifically and ethically; restrictions on placebo-controlled investigations will hinder the arrival of more efficacious and better tolerated antidepressants...
  27. ncbi request reprint Can we distinguish anxiety from depression?
    David S Baldwin
    Department of Psychiatry, University of Southampton, Hampshire, United Kingdom
    Psychopharmacol Bull 36:158-65. 2002
    ..There is still uncertainty regarding the neurobiological cause, but it is probably linked to dysregulation in the serotonergic and noradrenergic systems...
  28. doi request reprint Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders service
    H J Graystone
    Clinical Neuroscience Division, School of Medicine, University of Southampton, University Department of Mental Health, RSH Hospital, Brintons Terrace, Southampton, SO14 0YG UK
    J Affect Disord 114:305-9. 2009
    ..Social phobia is a common, persistent and disabling anxiety disorder in which co-existing depressive symptoms are common. However the prevalence of social anxiety symptoms in patients with other mood and anxiety disorders is uncertain...
  29. ncbi request reprint The Wessex Recent In-Patient Suicide Study, 2. Case-control study of 59 in-patient suicides
    E A King
    Mental Health Group, Department of Psychiatry, The University of Southampton, Southampton, UK
    Br J Psychiatry 178:537-42. 2001
    ..Psychiatric patients have an elevated risk of suicide while in hospital...
  30. doi request reprint Veterinary surgeons and suicide: a structured review of possible influences on increased risk
    D J Bartram
    Division of Clinical Neurosciences, School of Medicine, University of Southampton, RSH Hospital, Brintons Terrace, Southampton SO14 0YG
    Vet Rec 166:388-97. 2010
    ....
  31. doi request reprint A cross-sectional study of mental health and well-being and their associations in the UK veterinary profession
    David J Bartram
    Division of Clinical Neurosciences, School of Medicine, RSH Hospital, University of Southampton, Brintons Terrace, Southampton SO14 0YG, UK
    Soc Psychiatry Psychiatr Epidemiol 44:1075-85. 2009
    ..We aimed to assess the contribution of mental health and well-being to the elevated risk, through a postal questionnaire survey of a large stratified random sample of veterinary surgeons practising within the UK...
  32. ncbi request reprint Depression and sexual dysfunction
    D S Baldwin
    Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, UK
    Br Med Bull 57:81-99. 2001
    ..There is a need for further studies of the effects of antidepressants on sexual function...
  33. ncbi request reprint Elderly suicide rates in Asian and English-speaking countries
    C Pritchard
    Department of Mental Health, Faculty of Medicine, Health and Biological Sciences, University of Southampton, Southampton, UK
    Acta Psychiatr Scand 105:271-5. 2002
    ..Asian culture venerates elderly people. It was hypothesized that elderly suicides would be proportionately lower in Asian societies than in English-speaking countries (ESC)...
  34. ncbi request reprint Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatients
    Andrew G Mayers
    University Department of Psychiatry, University of Southampton, UK
    Hum Psychopharmacol 18:207-14. 2003
    ..Reports of poor sleep may be associated with reports of poor mood in depression, but in non-depressed individuals the association may be with a feeling of weariness...
  35. doi request reprint Impaired identification of fearful faces in Generalised Social Phobia
    Matthew Garner
    Division of Clinical Neuroscience, School of Medicine, University of Southampton, SO17 1BJ, United
    J Affect Disord 115:460-5. 2009
    ..The present study is novel in using a signal detection approach to clarify whether Generalised Social Phobia (GSP) is associated with biased identification of emotionally ambiguous facial expressions...
  36. doi request reprint Attentional biases in clinical populations with alcohol use disorders: is co-morbidity ignored?
    Julia M A Sinclair
    Mental Health Group, Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Hum Psychopharmacol 25:515-24. 2010
    ..To identify how psychiatric co-morbidity was identified and assessed, in studies of attentional bias in clinical samples of patients with alcohol use disorders (AUDs)...
  37. ncbi request reprint Antidepressants and their effect on sleep
    Andrew G Mayers
    Perinatal Mental Health, University of Southampton, UK
    Hum Psychopharmacol 20:533-59. 2005
    ....
  38. doi request reprint Research in anxiety disorders: from the bench to the bedside
    Matthew Garner
    School of Psychology and Division of Clinical Neurosciences, School of Medicine, University of Southampton, UK
    Eur Neuropsychopharmacol 19:381-90. 2009
    ..Clinical and neurobiological predictors of active treatment and placebo response are considered...
  39. ncbi request reprint Escitalopram: efficacy and tolerability in the treatment of depression
    David S Baldwin
    Community Clinical Sciences, Research Division, Faculty of Medicine, Health and Biological Sciences, University Department of Mental Health, University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG
    Hosp Med 63:668-71. 2002
    ..This review describes the properties of escitalopram, summarizes the results of randomized controlled trials, and suggests that escitalopram has advantages over citalopram in the treatment of depression...
  40. ncbi request reprint Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients
    Andrew G Mayers
    University Department of Psychiatry, University of Southampton, UK
    Hum Psychopharmacol 18:21-7. 2003
    ..These results confirm the extent of subjectively reported sleep disruption in depression and demonstrate the merit of combining the amended PghSD and QOLI to quantify sleep perceptions...
  41. ncbi request reprint Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder
    Karin Mogg
    Centre for the Study of Emotion and Motivation, School of Psychology, University of Southampton, Highfield, Southampton, SO171BJ, UK
    Psychopharmacology (Berl) 176:466-70. 2004
    ..Cognitive theories of anxiety, which provide the basis of cognitive-behaviour therapy, propose that such processing biases play an important role in causing and maintaining anxiety...
  42. ncbi request reprint Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?
    David S Baldwin
    Department of Psychiatry, Royal South Hants Hospital, Southampton, United Kingdom
    CNS Spectr 11:34-9. 2006
    ....
  43. ncbi request reprint The Wessex Recent In-Patient Suicide Study, 1. Case-control study of 234 recently discharged psychiatric patient suicides
    E A King
    Mental Health Group, Department of Psychiatry, The University of Southampton, Southampton, UK
    Br J Psychiatry 178:531-6. 2001
    ..Psychiatric patients have a higher suicide risk following hospital discharge...
  44. doi request reprint Interventions with potential to improve the mental health and wellbeing of UK veterinary surgeons
    D J Bartram
    University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG
    Vet Rec 166:518-23. 2010
    ..This paper proposes a portfolio of evidence-based interventions, for both organisations and individuals, which have the potential to improve mental health and wellbeing in the veterinary profession...
  45. ncbi request reprint Symptoms of fatigue and sleepiness in major depressive disorder
    David S Baldwin
    Faculty of Medicine, Health, and Life Sciences, University of Southampton, UK
    J Clin Psychiatry 67:9-15. 2006
    ....
  46. ncbi request reprint Agomelatine in the treatment of mood and anxiety disorders
    David S Baldwin
    Clinical Neuroscience Division, School of Medicine, University of Southampton, Southhampton
    Br J Hosp Med (Lond) 71:153-6. 2010
    ..What is its potential role in clinical practice?..
  47. ncbi request reprint Suicide in schizophrenia: a retrospective case-control study of 51 suicides
    Julia M A Sinclair
    Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK
    Schizophr Bull 30:803-11. 2004
    ..Suicide of individuals is difficult to predict in patients with schizophrenia. Young men appear particularly vulnerable at times of inpatient care. Depressive symptoms and previous suicide attempts are significant risk factors...
  48. ncbi request reprint Recurrent brief depression--more investigations in clinical samples are now required
    David S Baldwin
    Psychol Med 33:383-6. 2003
  49. ncbi request reprint The overlap of obsessive-compulsive disorder and social phobia and its treatment
    David S Baldwin
    Strategic Center of Excellence of Psychiatry, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    CNS Spectr 13:47-53. 2008
    ..Psychologic intervention should draw on the range of cognitive and behavioral approaches required for optimal outcomes in OCD and social phobia, as discrete conditions...
  50. ncbi request reprint What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Borwin Bandelow
    Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany
    J Clin Psychiatry 67:1428-34. 2006
    ..We also sought to compare the standardized effect sizes of escitalopram for these 4 psychiatric disorders...
  51. ncbi request reprint Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom
    Tine Rikke Jørgensen
    International Department of Health Economics and Epidemiology, H Lundbeck A S, Copenhagen, Denmark
    Ann Pharmacother 40:1752-8. 2006
    ..Generalized anxiety disorder (GAD) is associated with substantial economic burden...
  52. ncbi request reprint Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey
    Valerie S L Williams
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    J Clin Psychiatry 67:204-10. 2006
    ..The aim of this study was to estimate the prevalence and impact of sexual dysfunction during antidepressant treatment in 2 European countries...
  53. ncbi request reprint Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram
    Dan J Stein
    Department of Psychiatry, University of Cape Town, South Africa
    J Clin Psychiatry 67:1741-6. 2006
    ....
  54. doi request reprint Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale
    Jonathan Davidson
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Trent Drive, 4th Floor, Room 4082B, Durham, NC 27710, USA
    Int Clin Psychopharmacol 23:299-303. 2008
    ..The findings suggest that assessment of treatment response might be enhanced by routine evaluation of resilience...
  55. ncbi request reprint Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment
    David J Nutt
    Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK
    J Clin Psychiatry 67:46-9. 2006
    ..In addition, the faculty discussed the importance of patient psychoeducation and self-management as well as the ways in which disease models of depression affect treatment...
  56. ncbi request reprint Which antidepressants have demonstrated superior efficacy? A review of the evidence
    Stuart A Montgomery
    Imperial College School of Medicine, University of London, UK
    Int Clin Psychopharmacol 22:323-9. 2007
    ..This review of published data found evidence that only a very few antidepressants are shown to be more effective than others...
  57. doi request reprint Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
    Norman Sartorius
    Chairperson of CINP Task Force, 14 Chemin Colladon, Geneva, Switzerland
    Int J Neuropsychopharmacol 10:S1-207. 2007
  58. doi request reprint Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies
    Dan J Stein
    Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
    Eur Neuropsychopharmacol 18:422-30. 2008
    ..In conclusion, pregabalin, an alternative treatment option for GAD with a novel mechanism of action, also demonstrated efficacy in treating depressive symptoms typically encountered in GAD patients...
  59. doi request reprint Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement
    Hans Jurgen Moller
    Department of Psychiatry, Ludwig Maximilians University Munchen, Nussbaumstrasse 7, 80336 Munich, Germany
    Eur Arch Psychiatry Clin Neurosci 258:3-23. 2008
    ..It is the major problem facing efforts to identify the possible 'suicidal effects' of antidepressants...
  60. ncbi request reprint Suicide in depressive disorders: a retrospective case-control study of 127 suicides
    Julia M A Sinclair
    Centre for Suicide Research, UK
    J Affect Disord 87:107-13. 2005
    ..Depressive disorders are associated with a significant risk of suicide. Inpatient status and recent discharge from hospital have been identified as times of high risk of suicide within the course of illness...